<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02030678</url>
  </required_header>
  <id_info>
    <org_study_id>STao</org_study_id>
    <nct_id>NCT02030678</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer</brief_title>
  <official_title>To Evaluate the Clinical Effect of Irinotecan Monotherapy in Treatment of Local Recurrence or Metastatic Breast Cancer Patients Who Accepted at Least 2 Kinds of Chemotherapy Regimens Including Antharcycline or Taxanes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaoning Tumor Hospital &amp; Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic
      breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic
      breast cancer patients who recieved anthracycline or taxane drugs. The primary endpoint is
      Disease Control Rate and Progression free survival. The second endpoint is 3 or 4 grade
      Adverse Events 、overall survival.All the patients will recieve this therapy till disease
      progress or other occurrence of withdrawal standards.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic
      breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic
      breast cancer patients who recieved anthracycline or taxane drugs. The primary endpoint is
      Disease Control Rate and Progression free survival. The second endpoint is 3 or 4 grade
      Adverse Events 、overall survival. irinotecan 100mg/m2,iv,day1,day8,every 3cycles.If no AE
      happens, increase irinotecan dose to125mg/m2 at the second cycle.All the patients will
      recieve this therapy till disease progress or other occurrence of withdrawal standards.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>3cycles (21days/cycle)</time_frame>
    <description>Disease Control Rate:Completely Response+Partial Response+Stable Disease</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>irinotecan Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan , 100mg/m2, day1,day8, 3 cycles or till Progressive Disease or death</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <description>irinotecan , 100mg/m2,day1,day 8;21days a cycle;at least 3cycles.</description>
    <arm_group_label>irinotecan Hydrochloride</arm_group_label>
    <other_name>Kaiputuo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mestatic breast cancer patients whose disease recurrent after using anthracycline or
             taxane drugs

        Exclusion Criteria:

          -  Heart Disease.etc
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Sun, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liaoning Tumor Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Sun, Doctor</last_name>
    <email>jianong@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SunTao</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Sun, Doctor</last_name>
      <email>jianong@126.com</email>
    </contact>
    <investigator>
      <last_name>Tao Sun, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liaoning Tumor Hospital &amp; Institute</investigator_affiliation>
    <investigator_full_name>Sun Tao</investigator_full_name>
    <investigator_title>Director of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

